
Trump Administration’s FDA Commissioner Makes Psychedelics a Top Priority
Psychedelics and cannabis have experienced similar woes at the federal level. Both have received Schedule I classifications which places red tape on medical professionals seeking alternative treatments for their patients and expanding research that could …